Ethic Inc. Boosts Stake in GSK PLC Sponsored ADR $GSK

Ethic Inc. increased its position in GSK PLC Sponsored ADR (NYSE:GSK) by 9.1% in the third quarter, HoldingsChannel.com reports. The fund owned 174,093 shares of the pharmaceutical company’s stock after buying an additional 14,505 shares during the period. Ethic Inc.’s holdings in GSK were worth $7,514,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of GSK in the second quarter worth $25,000. SOA Wealth Advisors LLC. grew its holdings in GSK by 252.1% during the second quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 605 shares during the period. CoreFirst Bank & Trust acquired a new stake in GSK during the second quarter worth about $33,000. MTM Investment Management LLC purchased a new position in GSK during the second quarter valued at approximately $37,000. Finally, ST Germain D J Co. Inc. lifted its holdings in GSK by 225.2% in the second quarter. ST Germain D J Co. Inc. now owns 1,704 shares of the pharmaceutical company’s stock valued at $65,000 after acquiring an additional 1,180 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

Insider Activity at GSK

In other news, major shareholder Plc Gsk purchased 1,470,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was purchased at an average cost of $19.00 per share, for a total transaction of $27,930,000.00. Following the completion of the transaction, the insider owned 18,245,691 shares of the company’s stock, valued at $346,668,129. This trade represents a 8.76% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 10.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of GSK in a research note on Monday, October 27th. HSBC reissued a “reduce” rating on shares of GSK in a report on Wednesday, December 10th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of GSK in a report on Monday, December 22nd. Cfra set a $53.00 target price on shares of GSK in a research note on Thursday, October 30th. Finally, Wall Street Zen upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 5th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $44.13.

GSK Stock Down 0.0%

Shares of NYSE GSK opened at $49.08 on Tuesday. The firm has a market cap of $100.04 billion, a price-to-earnings ratio of 13.86, a price-to-earnings-growth ratio of 1.33 and a beta of 0.45. The company’s 50-day simple moving average is $47.41 and its 200-day simple moving average is $42.45. The company has a quick ratio of 0.55, a current ratio of 0.84 and a debt-to-equity ratio of 0.95. GSK PLC Sponsored ADR has a 52-week low of $31.72 and a 52-week high of $49.44.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.22. GSK had a net margin of 17.16% and a return on equity of 48.64%. The firm had revenue of $11.35 billion for the quarter, compared to analyst estimates of $8.21 billion. During the same period last year, the company posted $0.50 EPS. GSK’s quarterly revenue was up 6.7% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. Equities analysts predict that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 8th. Stockholders of record on Friday, November 14th will be paid a $0.4171 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $1.67 dividend on an annualized basis and a dividend yield of 3.4%. GSK’s payout ratio is currently 46.33%.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.